Taxonomy

CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C

The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news

Read More

CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMT

The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news

Read More

Gene Replacement Therapy in CMT4 Subtypes

The Charcot-Marie-Tooth Association (CMTA) has announced a $240K investment in

Read More

Nanoparticles for CMT1A, CMT1B, and CMTX1: A New Frontier in Gene Therapy

In a groundbreaking three-year joint project between the Charcot-Marie-Tooth Association

Read More

Repurposing Drugs for CMT1A: An Encouraging Approach

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form

Read More

DNA-Based Therapeutics: A Promising Future for CMT2E Treatment

Researchers at the University of Miami, supported by the Charcot-Marie-Tooth

Read More

CMT-SORD: Share Your Story

CMT-SORD: What is Your Story? For many with CMT, the

Read More

Chris Oviatt – Golfer with CMT

Chris Oviatt is a golfer from Oregon who was diagnosed

Read More

CMTA Announces New Center of Excellence in Thailand

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of

Read More

CMTA Appoints David Skarinsky to its Therapy Expert Board

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

Read More